Trial · NCT01214642
Results by group85
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 85
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Recommended Dose and Schedule for Phase 2 Studies | LY2523355 / LY2523355 +PEG | 8 | mg/m^2/day | ||
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 2 mg/m^2/Day | Serious AEs | 1 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 4 mg/m^2/Day | Serious AEs | 2 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 8 mg/m^2/Day | Serious AEs | 2 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 7 mg/m^2/Day | Serious AEs | 2 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 6 mg/m^2/Day | Serious AEs | 1 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 5 mg/m^2/Day | Serious AEs | 0 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 8 - 8 mg/m^2/Day | Serious AEs | 1 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5+PEG - 8 mg/m2/Day | Serious AEs | 0 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5+PEG - 12 mg/m^2/Day | Serious AEs | 0 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5+PEG - 16 mg/m^2/Day | Serious AEs | 3 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5+PEG - 14 mg/m^2/Day | Serious AEs | 2 | Participants | |
| Number of Participants With Clinically Significant Effects | Part B - Days 1, 5+PEG - 12 mg/m^2/Day | Serious AEs | 4 | Participants | |
| Number of Participants With Clinically Significant Effects | Part B - Days 1, 4+PEG - 12 mg/m^2/d | Serious AEs | 4 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 2 mg/m^2/Day | Other Non-Serious AEs | 3 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 4 mg/m^2/Day | Other Non-Serious AEs | 2 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 8 mg/m^2/Day | Other Non-Serious AEs | 6 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 7 mg/m^2/Day | Other Non-Serious AEs | 6 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 6 mg/m^2/Day | Other Non-Serious AEs | 6 | Participants | |
| Number of Participants With Clinically Significant Effects | Part A - Days 1, 5, 9 - 5 mg/m^2/Day | Other Non-Serious AEs | 3 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01214642/results